NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

I’ve read that about the IDH mutation testing being “decided at a late stage” here before, and it’s not really accurate. It appears that it was decided a long time ago that it would be collected at the end of the trial during final data collection, and used for label extension. This is from the article in the Journal of Translational Medicine published in May 2018, but written in the summer/fall of 2017, so almost three years ago.

The mutation status of the IDH1 gene has not yet been investigated for this trial, as this factor was not included in trial designs a decade ago when this trial began. It will be collected and analyzed later, but is unlikely to explain the overall survival results, as the mutation associated with prolonged survival occurs in less than 10% of newly diagnosed glioblastoma patients.

https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6